{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:27:35Z","timestamp":1767893255248,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer HealthCare SAS, France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti\u2013vascular endothelial growth factor (anti-VEGF) agents have become the standard of care in neovascular age-related macular degeneration (nAMD). Despite generally excellent response rates to anti-VEGF therapy, some patients do not respond or may respond suboptimally. In the case of refractory or rapidly recurring fluid in nAMD, clinicians may switch to another anti-VEGF agent. TITAN was an observational study that assessed the effectiveness and safety of intravitreal aflibercept (IVT-AFL) in patients with nAMD refractory to ranibizumab who switched to IVT-AFL after less than 12\u2009months of ranibizumab treatment in routine clinical practice in France.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>TITAN was an observational, retrospective and prospective 12-month study conducted at 28 centres in France. Patients with nAMD refractory to ranibizumab were enrolled. Patients who were switched from ranibizumab to IVT-AFL were followed for 12\u2009months. Data were obtained from medical records for retrospectively included patients, and at routine follow-up visits for those included prospectively. The main outcome measure was percentage of patients who achieved treatment success (gain of \u22651 Early Treatment Diabetic Retinopathy Study letters in best-corrected visual acuity [BCVA] and\/or any reduction in central retinal thickness [CRT]) from baseline to 12\u2009months after switching. A sample size of 225 patients was determined based on a 2-sided 95% confidence interval with a width equal to 0.12 when the sample proportion was 0.70.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We analysed safety data (<jats:italic>N<\/jats:italic>\u00a0=\u2009217) and clinical outcomes from patients in the per-protocol population (<jats:italic>n<\/jats:italic>\u00a0=\u2009125). The mean (standard deviation) number of IVT-AFL injections was 7.5 (2.6). Treatment success was achieved in 68.8% of patients. Mean BCVA change from baseline to Month 12 was +\u20091.5 letters (<jats:italic>P<\/jats:italic>\u00a0=\u20090.105) and the mean CRT change was \u2212\u200945.0\u2009\u03bcm (<jats:italic>P<\/jats:italic>\u00a0&lt;\u2009\u00a00.001). In a subgroup analysis, in patients who received three initial monthly IVT-AFL injections, mean BCVA gain was 3.3 letters at Month 12 (<jats:italic>P<\/jats:italic>\u00a0=\u20090.015). Excluding lack of efficacy and inappropriate scheduling of drug administration, the most common adverse event was eye pain (2.3%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Switching ranibizumab-refractory patients with nAMD to IVT-AFL may improve visual outcomes in some patients, particularly those who receive three initial monthly injections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02321241\">NCT02321241<\/jats:ext-link>. First posted: December 22, 2014; Last update posted: July 2, 2018<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-021-01841-6","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:34:39Z","timestamp":1613694879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration"],"prefix":"10.1186","volume":"21","author":[{"given":"Sam","family":"Razavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Giocanti-Aur\u00e9gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Souied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"issue":"4","key":"1841_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1517\/14656566.2012.658368","volume":"13","author":"M Ohr","year":"2012","unstructured":"Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother. 2012;13(4):585\u201391.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"1841_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1358\/dot.2012.48.5.1805931","volume":"48","author":"EA Verner-Cole","year":"2012","unstructured":"Verner-Cole EA, Davis SJ, Lauer AK. Aflibercept for the treatment of neovascular age-related macular degeneration. Drugs Today (Barc). 2012;48(5):317\u201329.","journal-title":"Drugs Today (Barc)"},{"issue":"14","key":"1841_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"1841_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57\u201365.e55.","journal-title":"Ophthalmology"},{"issue":"2","key":"1841_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","volume":"145","author":"CD Regillo","year":"2008","unstructured":"Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. 2008;145(2):239\u201348.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1841_CR6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","volume":"118","author":"U Schmidt-Erfurth","year":"2011","unstructured":"Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118(5):831\u20139.","journal-title":"Ophthalmology."},{"issue":"9","key":"1841_CR7","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","volume":"116","author":"DS Boyer","year":"2009","unstructured":"Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116(9):1731\u20139.","journal-title":"Ophthalmology."},{"issue":"5","key":"1841_CR8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046\u201356.","journal-title":"Ophthalmology."},{"issue":"1","key":"1841_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2011-301236","volume":"96","author":"S Binder","year":"2012","unstructured":"Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol. 2012;96(1):1\u20132.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1841_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/bjo.2011.203893","volume":"96","author":"MS Eghoj","year":"2012","unstructured":"Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21\u20133.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"1841_CR11","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.ophtha.2008.07.007","volume":"115","author":"S Schaal","year":"2008","unstructured":"Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008;115(12):2199\u2013205.","journal-title":"Ophthalmology."},{"issue":"2","key":"1841_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171\u201385.","journal-title":"Angiogenesis."},{"issue":"12","key":"1841_CR13","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology."},{"issue":"1","key":"1841_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/bjo.2011.204685","volume":"96","author":"JL Gasperini","year":"2012","unstructured":"Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol. 2012;96(1):14\u201320.","journal-title":"Br J Ophthalmol"},{"key":"1841_CR15","doi-asserted-by":"crossref","unstructured":"Blanco-Garavito R, Jung C, Uzzan J, Quaranta-ElMaftouhi M, Coscas F, Sahel J, et al. Aflibercept after ranibizumab intravitreal injections in exudative age-related macular degeneration: the ARI2 study. Retina. 2018;38(12):2285\u201392.","DOI":"10.1097\/IAE.0000000000001928"},{"key":"1841_CR16","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2147\/OPTH.S33372","volume":"6","author":"MW Stewart","year":"2012","unstructured":"Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012;6:1175\u201386.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1841_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ajo.2013.03.030","volume":"156","author":"Y Yonekawa","year":"2013","unstructured":"Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156(1):29\u201335 e22.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"1841_CR18","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/IAE.0b013e31828e8551","volume":"33","author":"N Kumar","year":"2013","unstructured":"Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33(8):1605\u201312.","journal-title":"Retina."},{"key":"1841_CR19","doi-asserted-by":"publisher","first-page":"273754","DOI":"10.1155\/2014\/273754","volume":"2014","author":"M Gharbiya","year":"2014","unstructured":"Gharbiya M, Iannetti L, Parisi F, De Vico U, Mungo ML, Marenco M. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int. 2014;2014:273754.","journal-title":"Biomed Res Int"},{"issue":"9","key":"1841_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1136\/bjophthalmol-2013-304829","volume":"98","author":"WB Messenger","year":"2014","unstructured":"Messenger WB, Campbell JP, Faridi A, Shippey L, Bailey ST, Lauer AK, et al. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2014;98(9):1205\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1841_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ophtha.2013.08.035","volume":"121","author":"AA Chang","year":"2014","unstructured":"Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology. 2014;121(1):188\u201392.","journal-title":"Ophthalmology."},{"key":"1841_CR22","unstructured":"Lucentis [prescribing information]. South San Francisco: Genentech, Inc.; 2018."},{"issue":"7","key":"1841_CR23","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1007\/s12325-019-00971-0","volume":"36","author":"T Empeslidis","year":"2019","unstructured":"Empeslidis T, Storey M, Giannopoulos T, Konidaris V, Tranos PG, Panagiotou ES, et al. How successful is switching from bevacizumab or ranibizumab to aflibercept in age-related macular degeneration? A systematic overview. Adv Ther. 2019;36(7):1532\u201348.","journal-title":"Adv Ther"},{"issue":"5","key":"1841_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.5301\/ejo.5000757","volume":"26","author":"KA Aghdam","year":"2016","unstructured":"Aghdam KA, Pielen A, Framme C, Junker B. Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results. Eur J Ophthalmol. 2016;26(5):473\u20138.","journal-title":"Eur J Ophthalmol"},{"key":"1841_CR25","unstructured":"Eylea [prescribing information]. Tarrytown: Regeneron Pharmaceuticals, Inc.; 2018."},{"issue":"1","key":"1841_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193\u2013201.","journal-title":"Ophthalmology."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-01841-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-021-01841-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-01841-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:39:00Z","timestamp":1613695140000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-021-01841-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1186\/s12886-021-01841-6","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"7 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bayer France received a positive statement from the CCTIRS (Comit\u00e9 Consultatif sur le Traitement de l\u2019Information en Mati\u00e8re de Recherche dans le Domaine de la Sant\u00e9: Advisory Committee on Information Processing in Material Research in the Field of Health) on 26 November 2014 and an authorization from the CNIL (Commission Nationale de l\u2019Informatique et des Libert\u00e9s: National Commission on Computer Technology and Freedom) on 24 December 2015 concerning the TITAN study. These gave Bayer the possibility to collect, analyse and use anonymised data of patients included in this study. All patients provided written informed consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SR: Consulting fees from Allergan, Bayer and Novartis; LK: Financial support from Novartis, Allergan, Bayer, Thea and Alcon; consulting fees from Alcon, Alimera, Allergan, Bayer, Roche and Novartis; research funding from Alcon, Alimera, Allergan, Bayer, Horus, Novartis and Thea Pharmaceuticals; AGA: Consulting fees from Alimera, Allergan, Bayer and Novartis; ID: Employee of Bayer HealthCare SAS; ES: Consulting fees and financial support from Allergan, Bayer, Novartis, Roche and Thea Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}